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ABSTRACT 
There is a lack of paediatric documentation concerning efficacy and safety of many 
drugs, which contribute to drug use outside the terms of the product license (off-label).  
In the present thesis, four studies (I-IV), using different settings and design to evaluate 
pharmacological treatment in children, with focus on off-label drug use, is presented.  
 
Outpatient records of purchased prescriptions were retrieved to investigate the 
frequency and characteristics of paediatric off-label prescribing (I). In Stockholm, 1.8 
prescribed drugs per child were purchased in the year 2000. Every fifth drug was 
classified as an off-label prescription. The proportion of off-label prescriptions was 
highest for topical drugs, due to lack of paediatric information.  
 
A survey of all adverse drug reaction reports to the Medical Products Agency 
concerning paediatric outpatients in the year 2000 was performed, to investigate the 
frequency of off-label drug prescribing (II). One hundred and twelve paediatric cases, 
corresponding to 158 adverse reactions were reported. One third of the reports were 
regarded as serious, and these were more often associated with off-label drug 
prescribing. Antiasthmatic drugs were most commonly reported. Psychiatric symptoms 
were the most commonly reported adverse drug reactions. 
 
Paediatric questions and answers to a Drug Information Centre in Stockholm were 
retrieved and analysed regarding off-label drug use and paediatric literature information 
adding to the labelling of the drug (III). During a 10-year period, 249 paediatric 
questions were handled. Every third question concerned off-label treatment, often 
concerning psychotropic drugs. In every other response to off-label questions, 
additional paediatric documentation concerning the drug was found in the literature.   
 
In a prospective, nation-wide, cross-sectional study, paediatric prescriptions and off-
label drug use to children at hospitals in Sweden were analysed (IV). Enrolment of 
more than 200 hospital departments resulted in data from 2947 paediatric patients, that 
received altogether11294 prescriptions within two two-day-periods in 2008. Half of all 
administered prescriptions concerned either off-label drug use or unlicensed or 
extemporaneously prepared drugs. Paracetamol was the most common drug used both 
on- and off-label. Absence of paediatric information was the main reason for the large 
proportion of off-label prescribing of carbohydrates and electrolytes in hospitals.  
 
This thesis has demonstrated substantial off-label prescribing to children in both 
primary and hospital health care. A common reason for this is the lack of paediatric 
documentation. Children have the same right as adults to well documented and safe 
drug therapy. Therefore, it is necessary to improve paediatric documentation through 
harmonization of existing scientific knowledge and clinical experience, improved 
structure of SPC information, and more appropriate administration forms. 
Furthermore, the documentation of drug treatment and its outcomes, including the 
reporting of adverse drug reactions, need to be improved.  
Keywords: Child, drug treatment, off-label, drug related problems, adverse drug 
reactions, drug labelling 
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SAMMANFATTNING (SUMMARY IN SWEDISH) 
Dokumentation om effekt och säkerhet av läkemedel till barn saknas ofta, vilket medför 
att barn förskrivs läkemedel utanför den godkända produktinformationen (off-label).  
I denna avhandling presenteras fyra olika studier (I-IV) med olika bakgrundsdata och 
design för att utvärdera läkemedelsbehandling till barn, med fokus på 
läkemedelsbehandling off-label.  
 
Expedierade läkemedel i primärvården analyserades för att identifiera hur vanligt 
förekommande off-label förskrivning av läkemedel till barn är i öppenvården (I). År 
2000 expedierades 1.8 läkemedel per barn i Stockholm. Vart femte läkemedel förskrevs 
off-label och andelen var störst för topikala läkemedel, framför allt på grund av 
avsaknad av pediatrisk dokumentation. 
 
Biverkningsrapporter till läkemedelsverket analyserades avseende frekvensen off-label 
förskrivning (II). Under 2000 inkom 112 rapporter, omfattande totalt 158 
biverkningssymtom, som gällde barn i primärvården. En tredjedel av rapporterna 
klassades som allvarliga och förekomsten av läkemedel förskrivna off-label var större 
bland dessa än bland de mindre allvarliga rapporterna. Psykiatriska biverkningar, 
respektive biverkningar av astmaläkemedel, var vanligast bland rapporterna. 
 
Frågor om pediatrisk läkemedelsbehandling besvarade vid en 
läkemedelsinformationscentral studerades för att identifiera läkemedelsbehandling off-
label och kartlägga tillgängligheten av dokumentation rörande barn och 
läkemedelsbehandling, utöver befintlig produktinformation (III). 
Läkemedelsinformationscentralen hade under en 10-årsperiod handlagt 249 frågor 
gällande barn. Var tredje fråga klassificerades som off-label, bland vilka psykofarmaka 
var vanligast. Dokumentation om läkemedels effekt och säkerhet på barn utöver den 
svenska produktinformationen återfanns i hälften av alla svar till frågor klassade som 
off-label.  
 
I en nationell, prospektiv tvärsnittsstudie undersöktes läkemedelsordinationer, on- 
och off-label, till barn på sjukhus i Sverige (IV) under två tvådagarsperioder 2008. 
Över 200 sjukhuskliniker rapporterade in data från 2947 vårdade barn, som erhållit 
totalt 11294 ordinationer. Hälften av alla ordinationerna klassades som antingen off-
label, licensläkemedel, eller läkemedel producerade ex tempore på apotek. 
Paracetamol var det vanligaste förskrivna läkemedlet både i enlighet med 
produktinformationen och off-label. Avsaknad av pediatrisk dokumentation var den 
vanligaste anledningen till off-label förskrivning för glukos och elektrolytlösningar. 
Off-label förskrivning till barn är frekvent förekommande både i primärvården och i 
slutenvård och vanligast anledning är att det saknas dokumentation för användning hos 
barn. Barn har samma rätt till väldokumenterade och säkra läkemedel som vuxna, varför 
det är nödvändigt att förbättra den pediatriska dokumentation. Detta kan ske dels genom 
att harmonisera existerande vetenskaplig kunskap och klinisk erfarenhet med 
produktinformationen och genom att strukturera dessa texter på ett bättre och mer 
ensartad sätt. Det behövs och ett bättra utbud av lämpliga beredningsformer för barn, 
samt en generellt bättre dokumentation av barns läkemedelsbehandling, inklusive en 
ökad spontanrapportering av biverkningar. 
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1 INTRODUCTION 
Several years ago, the underprivileged position of children with respect to optimal 
drug therapies was raised, and in recent years, paediatric drug treatment and the lack 
of documentation in children concerning the efficacy and safety for many drugs have 
drawn much attention. The licensing procedure of new drugs aims at ensuring their 
efficacy, safety, quality and positive risk-benefit balance. This is often based on 
clinical trials and post marketing surveillance in adults. As a result, many drugs are 
neither tested, nor licensed for use in children. Several researchers have demonstrated 
that paediatric patients routinely are prescribed drugs in an off-label manner, i.e. 
drugs used outside the terms of the authorised product license. This off-label drug use 
means that children receive drug treatment based on less scientific documentation, 
which may increase the risk of drug related problems. Historically, 
pharmacovigilance started due to observed untoward effects in foetuses; the 
thalidomide disaster [1]. Despite this, documentation of paediatric drugs still remains 
inadequate.  
 
Children have the same right as adults to receive safe and effective drugs, i.e. a 
correct drug, in a right dose, in the right way, for the right indication, for the right 
period of time and with correct information. Therefore, it is also important that the 
child’s use of drugs is thoroughly documented, as well as all adverse drug reactions 
and other drug related problems, to ensure drug safety.  
 
The present thesis includes four pharmacoepidemiological studies (I-IV) in children, 
including three retrospective register based investigations, using different sources of 
data, and one prospective, observational studies, all with different designs to identify 
and evaluate paediatric drug use, with focus on off-label treatment.  
 
1.1 Children, not small adults 
Treating children is different from treating adults with regard to several factors. 
Children are defined as all individuals from 0-18 years of age, where on one hand you 
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may have a premature infant that weigh only 500 mg and on the other hand a fully 
grown teenager, weighing 100 kg.  
During childhood, from birth to adult, the body develops and grows, and it is well 
known that pharmacokinetic responses to a drug, i.e. drug absorption, distribution, 
metabolism and excretion, in a child may differ substantially from that of an adult, 
For example, the elimination capacity changes throughout childhood.  It can be very 
low in the newborn, especially in the preterm neonate, due to immaturity of both the 
hepatic drug metabolising capacity and the kidney function, whereas the toddler and 
preschool child have an increased metabolic capacity and may require much higher 
weight-adjusted doses than adults [2, 3]. Also, the surface area-to-body weight ratio 
in children can be up to three times higher than in adults, which can lead to a larger 
proportion of absorption of topically administered drugs [4]. Suitable doses for 
children have often been derived by scaling from adult dosage. However, available 
methods do not give good enough estimates [5, 6]. Therefore, children cannot be 
regarded as small adults when it comes to deciding a suitable dose.  
 
Communication is another issue that is of great importance when treating children 
with drugs compared to adults, were we often have to rely on the parents to receive 
and give information about drug treatment depending on the developmental stage of 
the child. Young children may be unable to swallow whole tablets (or even pieces 
when a tablet is crushed and blended in a fluid). Therefore, adjusted administration 
forms are crucial for the paediatric population [7]. 
 
 
1.2 Paediatric drug use  
Around 100 million of the European population are children below the age of 18. In 
Sweden, the corresponding figure is more than two million. This group must be 
regarded as a substantial population with a potential need to use drugs [8]. Drug 
therapy is widely used to treat disease in childhood and several prescription and drug 
utilization studies in primary health care have shown that children, especially infants 
and preschoolers, receive considerable amounts of drugs [9-11].  
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A review including several prescription studies in outpatients showed that the 
prevalence of drug prescribing ranged from 51 up to 91% in certain age groups [10]. 
The average number of drugs prescribed per child and year was 1.1 in Sweden 2007 
[12], and varied in other countries from 0.8-3.2 drugs per child per year [9, 10]. 
The most commonly prescribed drugs in children are antibiotics for systemic use, 
followed by drugs for the respiratory system and analgesics [9-11].  
 
A few small studies have shown that children receive a substantial amount of over-the-
counter (OTC) drugs and natural remedies [13-17]. Surveys estimating the overall use 
of OTC drugs and natural remedies in the paediatric population are lacking. Natural 
health products are often regarded as harmless agents. However, untoward effects have 
also been documented for these kinds of products [18].  
 
Children receive considerable amounts of drugs at hospitals. However, large paediatric 
drug utilization studies estimating drug use in hospital care have been lacking.  
 
 
 
1.3 Paediatric use of drugs off-label and unlicensed drugs  
Within the present work, the term off-label is defined as any drug use outside the 
terms of the authorised product license, i.e. the summary of products characteristics 
(SPC). The term unlicensed applies to drugs that are not approved by medical 
regulatory authorities, e.g. the Swedish Medical Products Agency (MPA).  
 
Drug prescribing in children has been reported to be frequently carried out in an off-
label or unlicensed manner in hospital health care [19-29], particularly in neonatal 
care units [26, 28, 30-33] (Table 1).  
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Table 1: Studies of off-label and unlicensed drug treatment in hospital health 
care.  
Settings Subjects 
(n) 
Drugs 
(n) 
Off-label 
(%) 
Unlicensed/ 
EPD (%) 
Year Reference 
Hospital care 166 862 23 14 1996 [20] 
Hospital care 609 2013 18 6 1998 [19] 
Hospital care 624 2262 39 7 2000 [21] 
Hospital care 132 222 26 8 2000 [22] 
Hospital care 74 237 19 3 2001 [23] 
Hospital care  237 2139 18 48 2001 [24] 
Hospital care 1461 4265 60 NA 2002 [25] 
Hospital care 60 483 25 24 2006 [27] 
Hospital care 265 1450 17 NA 2008 [29] 
Hospital /Neonatal care 293 1017 44 28 2002 [26] 
Hospital /Neonatal care 108 628 36 13 2009 [28] 
Neonatal care  70 455 10 35 1999 [30] 
Neonatal care  105 525 59 16 2002 [31] 
Neonatal care  97 1442 47 11 2002 [32] 
Neonatal care 35 176 51 NA 2007 [33] 
 
In hospital or neonatal care studies, the proportion of paediatric off-label and 
unlicensed drug prescriptions varies between 10-60% and 3-48%, respectively (Table 
1) [19-27, 30-33].  
 
Prior to study I, off-label drug use among outpatients had been poorly investigated. 
At the same time frame as study I, several investigations were performed in different 
European countries (Table 2). The proportion of off-label and unlicensed 
prescriptions varied between 11-26% and 0.3-17%, respectively [7, 34-40]  
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Table 2: Studies of off-label drug prescription in primary health care.  
Settings Subjects 
(n) 
Drugs 
(n) 
Off-label 
(%) 
Unlicensed/ 
EPD (%) 
Year Reference 
Outpatients 989 2522 29 4 2000 [34] 
Outpatients 1175 3347 11 0.3 2000 [35] 
Outpatients 455661 1592006 13 NA 2002 [36] 
Outpatients 1802 1925 15 <1 2002 [37] 
Outpatients 19283 68019 23 17 2002 [38] 
Outpatients 6141 17453 14 15 2002 [26] 
Outpatients 18043 66222 21 17 2003 [7] 
 
 
Some studies regarded licensed drugs as unlicensed when the paediatric labelling in 
the SPC stated that the drug was not recommended for children or absence of 
paediatric documentation, or contraindicated for use in children [20, 24, 26, 39].Other 
studies excluded certain pharmacological treatment, i.e. intravenous glucose and 
sodium chloride solutions [27, 28].  
 
The most common therapeutic groups of drugs, both in primary and hospital health 
care, were antibiotics, analgesics and drugs for the respiratory tract [19-27].  
The main reason for a drug to be classified as off-label was that the dose, the 
frequency of administration, or the age of the patient was not in agreement with the 
drug labelling [19-27, 38].  
 
The proportions of off-label and unlicensed drug use in previous studies varies 
widely, both in primary (table 2) and hospital (table 1) care, which can partly be 
explained by the various settings of the paediatric care, e.g. single general practice or 
specialised unit or restrictions to a certain regional areas or a single study day. 
Another important source of variations is probably interpretations of the definition of 
off-label and unlicensed drug therapy, which makes it difficult to compare studies.  
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Extemporaneously prepared drugs (EPD) apply to drugs prepared at pharmacies and are 
important for the paediatric population. It is probably widely used, due to lack of proper 
drug forms or strengths necessary for children [41, 42]. Most studies [19-27, 30-33, 35, 
38, 39, 43] regarded EPD as well as licensed drugs, modified by i.e. crushing tablets or 
diluting drug solution, as unlicensed drugs. Little information exists to support the 
pharmacokinetics of EPD and they are rarely quality assured. Thus, the background 
documentation of EPDs is even poorer than that of drugs used off-label. The proportion 
of EPD use, and which drugs children actually receive, is another area that is poorly 
investigated.   
 
Very little has been published concerning what drugs children in Sweden actually 
receives, both licensed and unlicensed drugs, EPD and natural remedies, as well as the 
proportion of off-label prescriptions. A single Swedish paediatric department was 
included in a European study concerning off-label drug use, showing that 67 percent of 
children received at least one drug off-label[21]. No data concerning off-label use of 
drugs at Swedish neonatal care units or in paediatric outpatients have previously been 
published. Off-label drug treatment is mainly discussed as a paediatric issue, however, 
it is documented in adults as well [44]. 
 
 
1.4 Drug related problems and off-label drug treatment in children 
A drug related problem has been described as an event or circumstance involving drug 
therapy that actually or potentially interferes with desired outcomes. Drug related 
problems can be divided into several categories such as adverse drug reactions or drug 
use/administration problems [45]. Adverse drug reactions is regarded as an unintended 
drug response that occurred at doses normally used in humans for the prophylaxis, 
diagnosis or therapy of disease [46] 
 
Drug related problems comprise of a broad set of clinical situations and can be difficult 
to analyse and validate. Most studies focus only on adverse drug reactions (ADRs), and 
a fewer studies do also include other types of drug related problems. Drug related 
problems were found to be the cause of admission to hospitals for children in three 
studies with an incidence between 3.4% and 7.9% [47-49]. Potential adverse drug 
events in hospitals have been described to be three times more common in paediatric 
patients compared with adults [50]. 
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Several prospective studies indicate that ADRs in children, especially in hospitalised 
children, are of great clinical relevance [32, 51-53]. The overall incidence of ADRs in 
children in hospital care has been documented to range from a single or a few percent 
up to nearly one fifth of the study population [51-58]. In outpatients, between 0.5-9 % 
suffered from ADR [53, 59]. Serious reactions occurred in almost 40% of ADRs 
documented in paediatric hospital admissions [55] and accounted for about 10-12% in 
hospitalised children [54-57]. It has been suggested that up to one half of the 
documented drug related problems could have been avoided [47, 49, 60].  
Although the incidence of reported ADRs in children varies, probably due to different 
study settings and different sizes of study populations, similar rates of ADRs have 
been reported in various adult populations [61-64].  
 
A few studies has analysed the potential association between off-label drug use and 
the risk of ADRs [65-68]. In a prospective, hospital-based study (n=936), 35% of the 
given drugs were unlicensed or off-label and the incidence of ADRs was 4% among 
the licensed drugs and 6% among the unlicensed or off-label drugs [65]. Another 
prospective study, based on the prescribing habits of 39 participating physicians, 
nearly 20% of (n=1419) prescriptions to outpatients were regarded as off-label, and 
the incidence of ADRs (a total of 20 non-serious events) was about 1.4% for licensed 
prescriptions, compared with 2% for unlicensed or off-label drug prescriptions [66]. 
There are additionally two studies based on spontaneous ADR reports from hospital 
care [67, 68]. In the first study, based on 95 ADR reports, 25% of the reports 
concerned medicines used off-label [67] and in the latter study, based on 182 ADR 
reports, off-label drug use together with other incorrect use such as drug interactions 
was more often associated ADRs reports than drugs used in line with the product 
labelling [68].  
 
Medication errors, e.g. a drug given in an improper or unintended dose or route, are 
another area in paediatric health care of great importance [69, 70]. However, this issue 
will not be addressed within the present work.  
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Long-term pharmacovigilance studies, especially focusing on the impact of off-label 
drug use and drug related problems, are still missing in the paediatric population.  
 
 
1.5 Documentation of paediatric drug use 
During the last years efforts have been made through regulatory authorities to 
improve knowledge on paediatric drug therapy. As a consequence of the previous 
lack of paediatric data on medicinal products, a new legislation was introduced into 
the European Union in 2007 [71]. The new Paediatric Regulation aims to facilitate the 
development and availability of medicines for children, to ensure that those medicines 
are of high quality, ethically researched, and authorised appropriately and to improve 
the availability of information on the use of medicines for children. All this shall be 
achieved without subjecting children to unnecessary trials, or delaying the 
authorisation of medicinal products in adults. An analysis of at that time new drugs 
with marketing authorization revealed that among 45 new substances, 29 were of 
possible use in children, only 10 were licensed for paediatric use [72]  
 
Drug Information Centres (DICs), are established both in Europe and the United 
States [73-75], where evaluated drug information, similar to clinical consultations, for 
adults as well as for paediatric patients can be attained. In Sweden, the first centre 
was started at the Department of Clinical Pharmacology at Huddinge Hospital in 
Stockholm in 1974, through cooperation between clinical pharmacologists and 
information pharmacists. Today, this is one out of six regional DICs  in Sweden [76]. 
The DIC in Stockholm receives about 1000 questions per year , mainly concerning 
ADRs, drug interactions, drugs during pregnancy and breast-feeding and drug choice 
or dosing [73].  
No published study on paediatric drug treatment based on data from a DIC has been 
found, but there are three retrospective DIC-based analyses concerning the use of 
drugs during pregnancy or breast-feeding supporting DIC as an important source of 
evidence based information [77-79].  
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Inadequate labelling of paediatric drugs is often assumed to be due to the lack of 
scientific documentation in children. However, it has not been investigated to what 
extent available literature information concerning paediatric drug efficacy and safety 
outside the SPCs actually exists. Neither has it been studied how well a child’s actual 
drug use, licensed or unlicensed drug treatment nor EPD and natural remedies, are 
documented in the e.g. the medical records.  
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2 AIMS OF THE THESIS 
 
The main aim of this thesis has been to use an epidemiologic approach to describe 
different aspects of paediatric drug treatment today, as a basis for the guidance of 
further clinical studies, aimed at approving the documentation of the safety and 
efficacy of drug treatment to children. 
This main aim can be divided into the following, separate aims: 
• To investigate and characterise drug prescribing to children in Sweden, in 
primary health care, as well as in hospital care, and to analyse the extent and 
manner of off-label and unlicensed paediatric drug use in therapeutic areas. 
• To investigate clinical aspects of paediatric off-label drug treatment by  
a) characterising ADR reports concerning paediatric outpatients, including 
the proportion of both serious and non-serious ADR reports related to off-
label drug prescribing. 
b) analysing paediatric Questions and Answers at a Drug Information Centre 
regarding drug related problems and off-label drug treatment.  
• To analyse the availability of documented information, adding to the 
information of the paediatric labelling of drugs, in relation to paediatric drug 
related problems, as presented to a Drug Information Centre. 
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3 MATERIALS AND METHODS 
3.1 Settings and subjects 
Paper I:  
This is a retrospective analysis of pharmacy-dispensed drugs to children and 
adolescents regarding off-label prescriptions in the year 2000. A computerised 
population-based prescription database produced by the National Corporation of 
Swedish Pharmacies was used to analyse drug prescriptions to children less than 16 
years of age. In Sweden no prescription data could be individually linked at the time 
of the study. Therefore, the data have been analysed on an aggregated level.  
The drugs were ranked by purchased volume according to the number of prescribed 
items. The analysis was restricted to the Drug Utilisation 90% segment (DU90%) 
containing those drugs that accounted for 90% of the total number of prescriptions 
[80]. Off-label drug prescribing was assessed with respect to age, formulation and 
route of administration. The off-label assessment was validated through the 
independent analysis of a random sample of 50 different brand names by another 
researcher, and was found to be identical with the initial assessment. 
Furthermore, adherence assessment to regional guidelines was performed using the list 
of recommended drugs (The Wise Drug List) from the local Drug and Therapeutic 
Committee in Stockholm County [81].   
 
 
Paper II:  
Study II consists of a nation-wide survey of spontaneous ADR reports to the Medical 
Products Agency (MPA) in Sweden. The extent and characteristics of off-label 
prescribing were assessed among drugs included in the ADR reports. The SWEdish 
Drug Information System (SWEDIS) produced by the MPA was used to identify all 
reported ADRs in children or adolescents under the age of 16 during year 2000. Data 
collection and evaluation of the ADR reports are performed by the six regional 
pharmacovigilance centres.  
 
An ADR was defined according to the World Health Organization (WHO) [46]. Off-
label drug treatment was assessed on the basis of age, dose, indication, formulation, 
route and frequency of administration. ADR analysis and off-label assessment were 
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independently performed by two researchers and found to be identical. Population and 
aggregated drug utilization data were obtained from Statistics in Sweden [8] and the 
National Corporation of Swedish Pharmacies [82], respectively.   
 
A total of 444 ADR reports concerning children and adolescents younger than 16 years 
in Sweden were identified in the year 2000. Vaccines given to children are almost all 
licensed and labelled for use in the paediatric population and therefore, they were not 
included in the further analysis (n=308). Of the remaining 135 ADR reports, another 24 
reports were excluded for the following reasons: inpatients, newborns suffering from an 
ADR due to maternal drug treatment, unclassifiable causality, and OTC drug use. 
 
 
Paper III:  
All documented questions and answers (Q&A) handled by the DIC at Karolinska 
University Hospital-Huddinge, Sweden were used in this study. The Q&A are 
continuously registered in a local database, which also contains information concerning 
demographic data, drug and medical history of the patient, type of drug related problem 
and literature sources used.  
 
All Q&A during a ten-year period, from 1995 to 2004, were retrieved and 
systematically analysed. Out of a total of 6842 questions processed at the DIC from 
1995 to 2004, 300 (4,4%) were documented to concern children. Analysis was 
restricted to questions concerning children less than 16 years of age. In total, 51 (17%) 
of the questions were excluded from further analysis as the question concerned: breast-
feeding and/or pregnancy, patients 16 years or older, food, chemicals or doping 
substances, accidental ingestion of drugs, or multiple registration of the same question.  
Q&A were classified regarded off-label drug use and further analysed with respect to 
their content of evaluated literature information, adding to the information given in the 
labelling of the drugs in the SPC in the Swedish catalogue of medical products [83].   
 
 
Paper IV:  
All identified paediatric hospital departments, as well as a number of other departments 
that treat paediatric patients (e.g. departments of radiology and ear, nose and throat 
diseases), in Sweden were enrolled in this study. All 44 participanting hospitals 
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received written and oral information about the design and purpose of the study at 
several meetings, and special prescription forms were distributed by mail prior to the 
study periods.  
 
Data on concurrent drug prescriptions to paediatric patients in hospital care were 
collected during 48 hours in the middle of May and October 2008, respectively, by 
the treating nurses and/or physicians. The prescription form requested information 
about patient social security number, age, gender, weight and cause of hospital 
admittance, as well as name of  the drugs, indication, strength, dosage, form and route 
of administration, and estimated duration of drug treatment. Furthermore, the 
questionnaire requested information on whether the drug was used for the treatment 
or prevention of disease or for diagnostic purposes. Only patients 18 years of age or 
less who received any drug treatment were included in the final analysis.  
Data were entered and analysed in a database (Microsoft Access 2000). Data lacking 
in fields, such as route of adminstration, formulation, duration of treatment and cause 
of treatment,  were classified as unknown unless it was clearly described elsewhere in 
the prescription form.  
 
The off label analysis was performed for each prescription of a licensed drug. The off-
label assessment was validated through an independent analysis of a random sample 
of 20 percent of the different pharmaceutical compounds by a hospital pharmacist, 
and was found to be in accordance with the initial off-label analysis.  
To investigate the external validity of the data, information concerning all paediatric 
hospital admissions during the two study periods was retrieved from the National in-
hospital patient register from the National Board of Health and Welfare 
(Socialstyrelsen) [12].  
 
 
3.2 Classification  
3.2.1 Drugs (Paper I-V) and treatment guidelines (Paper I) 
Licensed drugs were classified according to the Anatomical Therapeutic Chemical 
(ATC) classification to the fifth level [84] and their license status was determined by 
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the SPC from the Swedish catalogue of approved medical products (FASS) as the 
primary reference source in studies I-IV [83]. A book with extemporaneously 
prepared drugs [85] (I,II,IV), contact with the manufacturer (I,II) or product 
information provided by the MPA homepage (I-IV) was used as secondary reference 
sources. In the first (I) and second study (II) FASS for the year 2000 was used, in the 
third study (III) FASS corresponding to the year of the questions and in the last study 
(V) SPC available online in the year 2008 was used. All drugs that were not listed in 
our primary or secondary reference sources mentioned above were regarded as 
unlicensed. 
 
3.2.2 Age groups (Study V) 
In study IV the paediatric patients were divided into four different age groups: 
neonates (0-28 days), infants (1-23 months), children (2-11 years) and adolescents 
(12-18 years). This was done in accordance with guidelines from the European 
Medicines Agency (EMA), with the exception that premature neonates were included 
in the neonatal group [86].  
 
 
3.2.3 Adverse drug reactions and other drug related problems (Paper II-III) 
In study II, each reported ADR was classified with respect to causality and seriousness. 
The level of causality was restricted to certain, probable or possible, using the WHO 
definitions [46]. We also classified each ADR as a type A (pharmacological) or type B 
(idiosyncratic) reaction.  
 
In study III, five different categories of drug related problems were used; ADR, drug 
interactions, drug kinetics, drug choice and/or dosing, drug formulation and/or 
administration, depending on the main objective of the DIC question [73, 76]. 
 
 
3.2.4 Off-label drug treatment (Paper I-IV) 
The off-label assessment was performed in the studies I-IV by analysing the license 
information for included drugs with the reference sources mentioned above (see 
3.2.1). Sections 4.1, 4.2, 4.3 and 4.4 of the SPC, which concern indications, dosages 
and way of administration, contraindications and warnings, were used to assess the 
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off-label status of prescribed licensed drugs. Also, a search for the terms 
“child/children” was performed on the complete SPC text. The term off-label was 
defined as any drug use outside the terms of the product license.  
 
 
Off-label presciptions were further divided into seven different categories as shown in 
table 3. 
Table 3: Descriptions of off-label categories 
Off-label category Description Paper 
Age Drug not recommended for a certain age-group in the SPC  I-IV 
Weight Drug not recommeneded for children below a certain 
weight in the SPC 
I-II,IV 
Absence of 
paediatric 
information 
Information of drug treatment to paediatric patients (less 
than 16 years of age) is not mentioned at all in the SPC 
I-IV 
Lack of paediatric 
clinical data/trials 
Stated lack of scientific data or clinical studies on drug 
efficacy and safety for paediatric patients (less than 16 
years of age) in the SPC  
I-IV 
Contraindicated Drugs stated in the SPC to be contraindicated in children I-IV 
Indications Drugs prescribed for indications not listed in the SPC II-IV 
Administration 
route 
Drugs administered by a route not approved according to 
the SPC 
I-II,IV 
 
Product information allowing paediatric use in general, without any age or dose 
specification, was regarded as on-label in paper I-III but rendered the prescribed drug 
an off-label status if given to patients less than 1 year of age in paper IV. This 
definition is based on the fact that there are well known age dependent differences in 
the pharmacological response to drugs and drug kinetics, especially in neonates and 
infants less than 1 year. A single prescription could be regarded as off-label in more 
than one category. 
 
In study II, drugs that exceeded a recommended dose by more than 20% were 
regarded as off-label, but not drugs given in less than the recommended dose.  
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3.2.5 Documentation of drug treatment in children (Paper III) 
In study III the content of evaluated literature information, adding to the labelling of 
the drugs, was assessed and categorised for all Q&As regarded as off-label drug 
treatment. Four different categories of information were used as shown in table 4. 
 
Table 4: Definition of categories of type of information.  
Category 
 
Type of information 
Age  
 
Age requirements for paediatric drug treatment 
 
Dosing Paediatric dosing recommendations 
 
ADRs 
 
ADRs not mentioned in the labelling of the drug 
 
Drug interactions Drug interactions not mentioned in the labelling of the drug 
 
 
 
3.3 Ethical considerations 
None of the registers used in study I-III contained any references to patient identity and 
therefore no ethical approval was needed for these studies. Study IV was approved by 
the Reseach Ethics Committee at Karolinska Institutet, Stockholm, no 2008/502-31/2.  
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4 RESULTS 
The results are summarised in this section. For a more complete account see the 
separate publications I-IV (Appendix).  
 
 
4.1 Drug treatment (Paper I-IV) 
There was a substantial use of drugs among children in all studies (I-IV) with an 
average use of 1.5-1.8 prescribed drugs per child in outpatients (I,II) and 3.8 drugs per 
child in hospital care (IV) as shown in table 5 
 
 
Table 5 Drug use and off-label proportion in Paper  I-IV.  
Study Subjects 
(n) 
Drugs (n) Median age 
(years) 
Off-label 
(%) 
Timeframe Setting 
I 357 784 575 526 7  21 Year 2000 Prescriptions in 
primary health care 
II 112 125 7  42 Year 2000 ADRs reports from 
primary health care 
III 249 298 NA 31 1995-2004 Q&A from a DIC 
IV 2947 11294 4  41 4 days 2008 Prospective cross-
sectional study in 
Hospital care 
(NA - not applicable) 
 
Children less than two years of age is an age group that receives a substantial amount of 
drugs as illustrated in Figure 1 (III) and Table 6 (IV). In primary care, the median age 
of children is higher, as shown in Table 5.  
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Figure 1 (Paper III): Number of questions and answers classified as within-label, off-
label and/or unlicensed with or without evaluated literature information, adding to the 
labelling of the drugs at a Drug information centre. 
 
0
5
10
15
20
25
30
35
40
45
0-1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Age (years)
N
um
be
r 
of
 Q
&
A
Off-label and/or unlicensed, with evaluated literature information
Off-label and/or unlicensed, without evaluated literature information
Within-label
 
(n=172 questions with known age)  
 
 
 
Table 6  (Paper IV): Distribution of prescriptions of licensed drugs, 
unlicensed drugs, extemporaneously prepared drugs and undocumented 
use of drugs by age groups in children at hospitals.  
Age groups Patients Prescriptions Licensed Unlicensed EPD Undocumented 
All 2947 11294 9471 516 1177 5608 
Median (SD) NA 3 (3.7) 2 (3.2) 1 (1.3) 1 (1.2) 2 (2.5) 
Neonates 476 1875 1271 (68) 139 (7.4) 428 (23) 1310 (70) 
Infants 698 2644 2134 (81) 132 (5.0) 320 (12) 1505 (57) 
Children 1043 3800 3378 (89) 130 (3.4) 274 (7.2) 1789 (47) 
Adolescents 730 2975 2688 (90) 115 (3.9) 155 (5.2) 1011 (38) 
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Infants and neonates received more than half of all prescriptions for a longer duration 
than one week, whereas children and adolescents received 74% of all prescriptions 
given as a single dose or on demand medication in study IV.  
 
 
Antibacterials for systemic use (i.e. phenoxymethylpenicillin, trimethoprime) and anti-
asthmatics (i.e. budesonide, terbutalin, salbutamol) were found to be the most 
commonly prescribed drugs to outpatients in paper I. which is in agreement with 
previous findings [9, 10]. In study III, the most common drugs in the DIC questions 
were antibacterials for systemic use (erythromycin, pivmecillinam), followed by 
antiepileptics (carbamazepine, valproate). Intravenous carbohydrates or electrolytes 
solutions (ATC B) as well as analgesic agents (ATC N), e.g. paracetamol and morphine, 
were commonly prescribed drugs among children at hospitals in paper IV (Figure 3). In 
paper IV the paediatric patients had been prescribed five percent unlicensed drugs and 
10 % EPD (Table 6).  
 
Among the ADR reports in the second study (II) and among the DIC questions (III), 
almost all drugs were systemically administered.  
 
 
The most frequently prescribed licensed drug groups, classified according to ATC-
codes in paediatric patients at hospitals (IV) were drugs for the nervous system (N), 
drugs for blood or blood forming organs (B) and drugs for infections (J) (Figure 2).  
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Figure 2 (Paper IV): Distribution of prescriptions of licensed drugs and off-label 
drugs for the main ATC subgroups in paediatric patients at hospitals. (Se also 
Table 7) 
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In paper III, 24% of the Q&A concerned unlicensed drugs or herbal remedies.  
 
Among EPDs, intravenous morphine, followed by intravenous caffeine and oral salt 
formulations were most common (IV). The most common unlicensed drugs were 
multivitamins and allergen extracts (IV).  
 
In paper IV, the age group of children (2-11 years) received the highest proportion of 
licensed drug prescriptions, whereas neonates (0-28 days) and infants (1-23 months) 
were given the highest proportion of EPDs and unlicensed drug prescriptions (Table 
6). Neonates and infants received 53% of all unlicensed prescriptions and 64% of all 
EPD prescriptions (Table 6).  
 
 
4.2 Off-label drug use (Paper I-IV) 
Off-label drug treatment in children was the main topic of interest for all of the papers 
I-IV. More than one fifth of prescribed drugs for all age groups were classified as off-
label in paper I, and this proportion was even higher among outpatients in ADR reports 
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(II). In the third study (III), we found that more than every third question to the DIC 
concerned off-label drug treatment (Table 5). In study IV the off-label proportion was 
more than 40%. Every other prescription to a child in a Swedish hospital was classified 
either off-label or an EPD or an unlicensed drug.  
 
 
The proportion of off-label drug use was highest among adolescents (12-15 years) in 
study I (29%) and III, whereas in study IV, it was highest for neonates and infants 
(Table 6).  
 
The proportion of drugs used off-label varied considerably between therapeutic groups 
and between the different studies. The proportion of off-label drug prescriptions in 
outpatients (I), was found to constitute more than 70% of dermatological drugs (e.g 
hydrocortisone, fucidid acid). In the ADR reports (II) off-label drug use was most 
common among drugs for the respiratory system (e.g montelukast, budesonide). 
Among paediatric Q&A from a DIC, off-label drug use was most common among 
drugs for the nervous system (e.g. risperidone, selective serotinine reuptake inhibitors) 
(III). 
 
 
Among paediatric patients in hospital care (IV) drugs for the blood and blood forming 
organs (e.g. carbohydrates and/or electrolyte solutions), the nervous system (e.g. 
paracetamol, morphine, midazolam) as well as drugs for the alimentary tract and 
metabolism (e.g. docusate sodium, potassium citrate, eso- omeprazole) had the highest 
number of off-label prescriptions. Other drugs with a high clinical important proportion 
of off-label drug use were found (IV), e.g. drugs used for cardiovascular diseases and 
different allergy tests (table 7).  
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Table 7: The most commonly prescribed licensed substances (Rx (no)- 
number of prescriptions) used in an off label manner (n=3905) in each 
ATC group in paediatric patients at hospitals (IV). 
 ATC Rx (no) Off-label 
(%) 
Most common substances  
A 1306 37 Docusate sodium, potassium citrate, eso- omeprazole 
B 1736 71 Carbohydrates, electrolytes 
C 531 53 Epinephrine, furosemide, clonidine 
D 54 83 Tar like, hydrocortisone/mikonazole 
G 23 61 Magnesium hydroxide, sildenafil 
H 291 38 Prednisolone, betamethason 
J 1360 19 Sulfamethoxazole/trimetoprim, ampicillin 
L 155 28 Azathioprine, etoposide 
M 494 27 Diclofenac, ibuprofen 
N 2503 36 Paracetamol, morphine, midazolam 
P 19 5 Pentamidine isethionate 
R 660 32 Budesonide, salbutamol 
S 59 92 Chloramphenicol, fusidic acid 
V 280 49 Different allergy tests 
 
 
The main reasons for drug use in an off-label manner in nearly all studies 
(I,II,IV) was found to be lack of paediatric labelling, rather than explicit 
prohibitions of paediatric use, followed by a non-approved dose in relation to 
age or weight in study II and IV. Lack of paediatric drug labelling was found 
for several drug groups, such as topically administered drugs in paper I, and in 
paper IV for carbohydrates and electrolytes, analgesic drugs, laxatives and 
proton pumps inhibitors.    
 
 
In study IV, five percent of all the prescriptions were administered in a way not in 
agreement with the intended route of administration. The most frequent aberrant route 
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of administration was the use of an intravenous drug formulation for oral 
administration (carbohydrates, electrolytes, midazolam) or inhalation (epinephrine). 
 
4.3 Drug related problems (II-III) 
Off-label drug prescribing in study II were more often associated with serious (51%) 
than non-serious (39%) ADR reports, and reported ADRs were three times as often 
classified as type B (idiosyncratic) than type A (pharmacological) reactions.  
 
In paper III, adverse drug reactions and drug choice or dosing in children were most 
common in the DIC Q&A (Table 8).      
 
Table 8: Proportion of drug related problems, off-label drug treatment and 
evaluated literature information, in addition to the labelling of the drugs, in 
Q&A to a DIC. 
Drug related problem  
 
All  
[n (%)] 
Off-label  
[n (%)] 
Literature information 
[n (%)] 
All 249 (100) 78 (31) 41 (16) 
 
Adverse drug reactions 
 
91 (37)  20 (26) 8 (20) 
Paediatric drug choice and dosing 
 
85 (34) 31 (40) 21 (51) 
Drug interactions 
 
31 (12) 9 (12) 6 (15) 
Drug formulation and administration 
 
25 (10) 5 (6) 1 (2) 
Paediatric drug kinetics 
 
17 (7) 6 (8) 5 (12) 
 
 
Among the most common ADRs, in ADR reports (paper II) and/or Q&A (paper III) 
from a DIC, were symptoms from the central nervous system, skin reactions, 
gastrointestinal, and haematological symptoms (Table 9).  
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Table 9: Numbers and proportions of the most common kinds of ADRs in study 
II and III. 
Adverse drug reactions Study II           
[n (%)] 
Study III       
[n (%)] 
All  158 (100) 91 (100) 
Central nervous system disorders 
(sleeping disorders, aggressiveness, headache, paresthesia) 
54 (34) 17 (19) 
Skin reactions, allergic reactions 
(urticaria, exanthema, allergy) 
29 (18) 14 (15) 
Gastrointestinal  symptoms 
(nausea, vomiting, abdominal pain) 
19 (12) 3 (3) 
Hematological symptoms 
(leucopenia, thrombocytopenia, bleeding complication) 
14 (9) 14 (15) 
Systemic inflammaroty reactions 
(meningitis, pancreatitis) 
13 (8) 9 (10) 
Miscellaneous 
(abuse, adverse effects of the eye and respiratory tract) 
29 (18) 34 (37) 
 
 
 
4.4 Pediatric documentation of drug treatment (I,III) 
In the third study (III), more than half of the answers to off-label questions were found 
to contain evaluated paediatric drug information, that added to the information of the 
SPC. Mostly, additional information concerning drug choice or dosing was found 
(Table 8). Scientific papers from medical databases, e.g. PubMed, and medical 
handbooks were the most common sources for paediatric documentation, which 
consisted mainly of documentation of treatment concerning paediatric age requirements 
and dose recommendations.  
 
Within the DU90% segment, 61% of prescription items in study I corresponded to 
drugs that were recommended in the local treatment guidelines.  
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5 DISCUSSION 
5.1 Off-label drug treatment 
5.1.1 Some clinical aspects 
This thesis confirms that paediatric patients, both in primary and hospital health care, 
are subject to a large proportion of drug treatment that is not approved by regulatory 
authorities, meaning that the safety and efficacy of this drug treatment is neither well 
studied, nor sufficiently documented. Off-label drug treatment is, however, a 
multifaceted concept that may be of different clinical importance in different treatment 
situations. For example, the proportion of off-label drug use is apparently higher in 
hospitals than in primary health care, whereas primary health care involves a larger 
population of children under less intense medical supervision.  
 
The highest off-label drug use in paediatric hospital care consisted of intravenous 
carbohydrates and electrolytes, given orally to neonates and infants. From a purely 
pharmacological point of view, this treatment, based on long time clinical experience, 
probably represents minimal risks and the benefits are quite clear. On the other hand, 
to administer drugs by an unintended route may be associated with a high risk for 
administration errors. 
 
Neonates, in particular, and infants have a substantial off-label drug use, as well as the 
highest use of EPDs and unlicensed drugs in hospital care. Since neonates and infants 
are particularly vulnerable, due to their immature renal and hepatic function, as well as 
body proportions, difficulties in drug administration and ability to express adverse drug 
reactions, further evidence of both safety and efficacy of drugs is urgently needed in 
these age groups. The margins when a wrong dosage is given are smaller for young 
children compared to adults. 
 
Adolescents were frequently prescribed off-label drugs in primary health care and 
probably receive doses similar to that of the adults. However, it has been shown that 
adolescents can have other patterns of adverse drug reactions to e.g. antidepressive 
agents [53], indicating that adolescents have another sensibility to drugs than adults, 
despite having approximately the same body size.  
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Drugs administered topically to children were often classified as off-label in the studies 
of this thesis, both in hospital and primary health care. The reason for the off-label 
classification is mainly lack of paediatric information in the drug label, although a large 
clinical experience of topical drug treatment exists. The fact that only few ADR reports 
concern topically administered drugs may partly be due to a belief among prescribers 
that these drugs have a lower propensity to cause ADRs, than do systemically 
administered drugs. However, children do have a higher surface to body weight ratio 
than adults, and it has been observed that e.g. topically administered tacrolimus can 
give rise to high blood concentrations in children [87]. The potential risks of specific 
topical drugs, like e.g. immunosuppressants, need to be further studied, and drug 
labelling needs to be improved. Topically administered drugs in general, however, 
should perhaps not be regarded as the most prioritized drugs for further studies. 
  
 
5.1.2 Antipyretics and analgesics 
Paracetamol is, according to these studies, the most commonly used drug to treat 
fever and pain in children in primary health care, with or without a prescription, as 
well as in hospital care. Still, the off-label use of paracetamol is substantial, mainly 
due to off-label classification for age or weight, i.e. the drug was given to a child 
younger or smaller than specified in the dosage recommendations. This can partly be 
explained by unclear age definitions in the SPC. Although paracetamol is generally 
considered safe in paediatric care, a previous Cochrane review pointed out that there 
is limited evidence regarding the efficacy and safety for paracetamol in the treatment 
of fever in children [88].  
 
Other analgesics, such as opiods or diclofenac, have been highlighted by others in the 
past [19-21, 24, 30, 32, 36, 89] and by us, as areas were clinical trials appear to be 
needed to obtain appropriate dosages for all age groups and better paediatric drug 
labelling. Analgesics have also been listed on the EMAs priority list of paediatric 
drugs to be further studied [90].  
 
5.1.3 Galenic aspects 
The high rate of use of EPDs, unlicensed drugs or drugs administered off-label 
strongly supports the need for improvement by the manufacturers in providing 
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appropriate and approved galenic preparations suitable for children of different size 
and age [19, 22, 25]. Examples of very commonly used drugs that are lacking 
appropriate dosage forms include caffeine citrate oral solutions, intravenous morphine 
solution 1mg/ml and 0.05mg/ml, and the oral vitamin solution, Protovit®, used in 
neonatal and infant care, that was withdrawn in 1989 due to low sales numbers and is 
now only available as an unlicensed drug [91]. Drugs and Therapeutic Committees 
may play a role here, in promoting the use of drugs that are available in dose sizes or 
forms that are suitable also for paediatric use. 
 
5.1.4 The paediatric drug label 
Lack of paediatric labelling was one of the most common reasons for off-label drug use 
in nearly all of the studies (paper I,III,IV) presented in this thesis. However, we found 
that additional documentation concerning paediatric use, outside the drug label of the 
SPC, was often available via e.g Pubmed. One reason for paediatric off-label drug 
treatment is therefore the lack of harmonisation between paediatric documentation in 
the existing literature evidence and the authorised drug label. It is not feasible for all 
physicians responsible for paediatric prescribing to conduct Pubmed literature searches 
themselves every time they prescribe a drug off-label. They need of readily available, 
processed, evaluated and continuously updated information. In individual patient cases, 
this can obviously be provided by the DICs. However, there is also a need for expert 
groups devoted to paediatric drug treatment within the organisation of the Drug and 
Therapeutic Committees, which could continuously process new literature data and 
convey relevant information to physicians in both hospital and primary health care. 
Such a group has now been implemented in the work of the Drug and Therapeutic 
Committee of Stockholm County Council. 
 
 
5.1.5 Drug related problems 
Use of drugs in an off-label manner have been shown, by us and by others, to be more 
often associated with ADRs than drugs used according to the SPC [29, 65-68]. Whether 
this finding is significant or generalizable to all off-label drug use is not possible to 
determine.  
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In one study presented in this thesis, reported ADRs in children where more often 
idiosyncratic (type B) than due to the known, pharmacological action of the drug 
(type A). This is true for all spontaneous ADR reporting, also in adults. However, it is 
not known if the true incidence of type B reactions is higher in paediatric patients 
compared with adults.  
 
While licensed drugs are monitored by epidemiological surveys and post marketing 
studies of safety, there is currently no clear process for collecting information on 
ADRs for EDP or unlicensed drugs. Therefore spontaneous reporting of ADRs can be 
the only way of discovering hazardous effects, even though it is well known that the 
spontaneous reporting system is subject to substantial under-reporting [92, 93]. The 
annual reporting rate for non-vaccine related reports in Sweden is approximately the 
same today, as in the year of 2000, when study II was performed.  
 
The drug related problems presented in the questions to the Drug Information Centre in 
study III did not always relate to past events. Sometimes the questioner asked prior to 
prescribing a drug. The DIC service can thus hopefully be of aid in preventing some 
drug related problems in children. It has been shown that the DIC has a cost-saving 
potential in preventing ADRs in general [94].  
 
 
5.2 Documentation of paediatric drug treatment in health care  
It has been shown that physicians are well aware of the lack of paediatric labelling 
[95]. One reason for treatment with drugs in an off-label manner is probably that 
paediatricians have clinical experience that supports off-label drug use. Even so, all 
drug treatment, including the use of drugs in an off-label manner, needs to be 
thoroughly documented in the medical record of the patient.  
 
With the development of electronic, computerized patient record systems, structured 
documentation of off-label and unlicensed drug use, including the clinical outcomes 
of such treatment, could greatly improve the knowledge in this area. There are, 
however, some obstacles to this development. For example, some electronic record 
systems are not designed to document drug treatment in a structured way. Even today, 
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many systems lack a separate “drug treatment module”, and existing such modules 
may not be well suited for the documentation of paediatric drug use.  
 
 
Furthermore, health care personnel are not always very good at collecting relevant 
information concerning drug use, and this may be especially true in the treatment of 
children, in whom drug treatment may not be in focus. According to our own, 
unpublished data, less than half of the drugs used by 272 children prior to visiting an 
emergency room at the Karolinska University Hospital, were documented in the 
medical record. According to a structured and validated questionnaire, answered by 
patients/guardians in the waiting room, 40 percent of the children had used at least 
one prescribed drug, 65 percent had used at least one OTC drug and 8 percent had 
used natural remedies or alternative medicines before visiting the emergency room.  
Looking into the medical records from the visits, the heading “Medicines” was found in 
only 28 percent of the records. Information concerning use of drugs, OTC, or 
complementary medicine, ongoing or prior to the visit to the emergency room was, 
however, mentioned in the text in 58 percent of the records. In more than half (54 %) of 
the patients’ records, there was at least one drug missing, compared with the 
information in the questionnaire. More than two-thirds of the missing medicines were 
OTC drugs and only nine of the 22 different natural remedies were documented in the 
medical records (table 10).   
 
Table 10: Drugs use prior to visiting the hospital as documented from a 
questionnaire answered by 272 patients/guardians in the paediatric emergency 
waiting room and in the medical records from the same visit. 
 
Number of drugs in 
the questionnaire 
Percent of drugs missing 
in the medical records 
All  458 51% 
Prescribed drugs 182 29% 
OTC 254 65% 
Natural products 22 77% 
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5.3 Some methodological considerations 
Comparison of our data with studies in other countries regarding the proportion of off-
label prescribing and reason for off-label drug use is difficult due to a high variety of 
settings, small datasets and varying definition of off-label status among previously 
published studies in this field. The definition of off-label treatment needs to be clarified 
and standardized in order to be able to compare data in future studies.  
 
In primary health care, one fifth of the prescription was classified as off-label, which 
may not be a high number, particularly if topical drugs are excluded. The use of fewer 
off-label categories probably results in an underestimation of the off-label proportion. 
The reason for using different off-label categories is often due to limitations in the 
available data.  In study I and III, for example, a dose assessment was not possible, 
since the dose was not known at all in the study I and only in a few questions in study 
III.  If we had been able to analyse the dose in relation to the off-label assessment in 
study I, the off-label proportion might have been higher due to either too low or too 
high paediatric doses [96].  
 
In our first study (I) we focused on those drugs accounting for 90% of the prescription 
(DU90%) for practical reasons. The remaining 10% of the drugs prescribed are used 
more rarely and perhaps even more often lack paediatric labelling. Therefore, use of 
DU90% in this study could have contributed to an underestimation of the off-label 
proportion of outpatient drug prescribing.  In future studies it would be of greater 
interest to investigate all prescribed drugs.  
 
In paper IV the data collection depended on the work by attending paediatric hospital 
care professionals, and the vast majority of prescription forms appeared to be 
carefully completed. Comparing with statistical information on hospital admissions, 
the study appears to have captured information from at least 70 percent of all 
admitted children during the study periods, which supports that our data reflect 
paediatric drug use at Swedish hospitals in general [12]. Therefore, we believe that 
the study provides a good estimation of the current drug use by children at Swedish 
hospitals.  
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It cannot be excluded that the high use of EPD morphine and glucose found in study 
IV could be slightly overestimated, due to unclear documentation in the prescription 
form. Some of these EPD prescriptions could have been licensed drugs that had been 
diluted by the health care provider, which still would correspond to off-label drug use 
for morphine.  
 
 
5.4 Future studies and challenges 
The extensive collection of data in our last study on drug treatment to children at 
Swedish hospitals (IV) allows for several in-depth studies on different age groups 
and/or different therapeutic areas. Primarily, a study of the drugs prescribed to 
premature infants is planned. Other studies that are planned are a deeper investigation 
of EPD and unlicensed drugs, as well as calculations of defined daily dosages for 
certain drugs.  
 
To improve the documentation on drug efficacy and safety in children, attempts have 
been made by medical authorities (US Food and Drug Administration and European 
Medical Agency) to stimulate drug industry to perform paediatric clinical trials and 
submit paediatric labelling information [97, 98]. These attempts have included some 
economic incentives regarding patent protection [97] for both newly authorised drugs 
[99] and drugs already on the market [100].  However, it will take several years before 
these initiatives will have a large impact on the paediatric documentation of drugs in 
general. Study IV was performed as part of a pan-European effort, organised via EMA, 
to collect data on the current situation of paediatric drug use and prescribing. These 
data are meant to serve as a basis for the allocation of economic incentives to the 
medical academia to perform studies on the efficacy and safety of drugs that are of 
special concern in the paediatric population, which is in process.  
 
There are numerous examples of ambiguity of, or inappropriate and inconsistent 
descriptions of paediatric information in the SPC texts. For example, omeprazole 
tablets and esomeprazole oral formulas are on-label for paediatric use, whereas the 
intravenous administration form is off-label. In many SPCs, it is also mentioned that a 
certain drug should not be given to children or can be given to children, without any 
further definition of any age limits. Thus, an important issue concerning off-label drug 
use in the paediatric population is to harmonise the paediatric labelling regarding 
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administration forms, age definitions and between drugs from different drug 
manufacturers. Regulatory authorities could also guide manufacturers to avoid 
recommendations that e.g. suppositories or tablets should be divided several times to 
children. Thus, they would also support the production and availability of more 
appropriate administration forms for the youngest patients. It would also improve the 
documentation of paediatric drug treatment if the approval process and design of SPC 
was based on the patient's needs rather than economic interests. 
 
Although harmonization and clarifications of the SPC would be a great improvement, 
the information also needs to be made readily available to the prescribers, preferably 
through computerized clinical decision support system.  In such a system, evaluated 
clinical documentation and scientific data, in addition to SPC information, could 
be presented to the prescriber in an easily accessible way at the moment of 
prescribing.   
  
The lack of scientific documentation concerning drug safety and efficacy in children 
also applies to OTC drugs and herbal remedies. It has been suggested that children 
are subject to substantial self-medication by their guardians with these types of 
pharmaceuticals [48]. Greater efforts and resources should be devoted to research in 
this area, primarily to evaluate the possible hazardous effects in children and develop 
surveillance network for paediatric drug treatment.  
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6 CONCLUSIONS 
Off-label drug prescribing to paediatric patients is substantial, both in primary and 
hospital health care, and must be regarded as a patient safety issue.  
 
Off-label prescribing was a common phenomenon among drugs reported to have 
caused an ADR in paediatric outpatients, and was more often found in serious than 
non-serious ADR reports.  
 
The most vulnerable paediatric group, neonates and infants, have the highest exposure 
of drugs given at hospitals in an off-label manner, as well as extemporaneously 
prepared and unlicensed drugs.  
 
Off-label paediatric drug prescribing remains a public health concern and further 
clinical trials in children, as well as more focused interventions, such as careful post-
marketing surveillance of drug safety are needed.  
 
A harmonization of SPC texts with regard to the structure of the paediatric information, 
to available scientific evidence, to differing information between drug manufactures, 
and to inconsistencies between e.g. different administration routes is also urgently 
needed, and would greatly reduce the degree of off-label drug use in children.  
  
Other sources of information, besides the SPCs, are also needed to ensure safe and 
effective drug treatment in children, such as Drug Information Centres, dedicated Drug 
and Therapeutic Committees and clinical decision support systems.  
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